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The ﬁrst three-dimensional structure of a human Fc fragment genetically
engineered for the elimination of its ability to mediate antibody-dependent cell-
mediated cytotoxicity and complement-dependent cytotoxicity is reported.
When introduced into the lower hinge and CH2 domain of human IgG1
molecules, the triple mutation L234F/L235E/P331S (‘TM’) causes a profound
decrease in their binding to human CD64, CD32A, CD16 and C1q.
Enzymatically produced Fc/TM fragment was crystallized and its structure
was solved at a resolution of 2.3 A ˚ using molecular replacement. This study
revealed that the three-dimensional structure of Fc/TM is very similar to those
of other human Fc fragments in the experimentally visible region spanning
residues 236–445. Thus, the dramatic broad-ranging effects of TM on IgG
binding to several effector molecules cannot be explained in terms of major
structural rearrangements in this portion of the Fc.
1. Introduction
The relationship between the biological activity of human immuno-
globulin G (IgG) molecules and their effector functions has been well
established. Indeed, efﬁcient antibody-dependent cell-mediated
cytotoxicity (ADCC) and complement-dependent cytotoxicity
(CDC) have been invoked as crucial determinants in the efﬁcacy of
various therapeutic antibodies (Anderson et al., 1997; Green et al.,
2000; Cartron et al., 2002; Weng & Levy, 2003). Conversely, the
elimination of antibody effector functions could play a role in
decreasing IgG-mediated toxicity events, as shown for the CDC
activity of the anti-CD3 monoclonal antibody OKT3 (Xu et al., 2000).
ADCC and CDC are triggered by the binding of various effector
molecules to the Fc portion of IgG molecules. Mutational studies
have identiﬁed several ‘hotspots’ for Fc binding to the ﬁrst compo-
nent of complement activation C1q and to various ADCC-promoting
Fc  receptors (CD64/32A/16). In particular, lower hinge positions
234 and 235 were shown to have a strong modulating effect on human
Fc binding to human CD64 (Canﬁeld & Morrison, 1991; Chappel et
al., 1991; Hezareh et al., 2001), CD32A (Hezareh et al., 2001; Armour
et al., 2003), CD16 (Hezareh et al., 2001) and C1q (Xu et al., 2000;
Hezareh et al., 2001). Likewise, CH2 position 331 was shown to be a
major determinant for human IgG binding to human CD64 (Canﬁeld
& Morrison, 1991) and C1q (Tao et al., 1993; Idusogie et al., 2000).
One particular set of substitutions, L234F/L235E/P331S (referred
to hereafter as ‘TM’), results in a profound decrease in the binding
activity of human IgG1 molecules to human C1q, CD64, CD32A and
CD16 (this study). In an effort to shed light on the mechanisms by
which TM negatively affects these interactions, we solved the X-ray
crystal structure of a human IgG1 Fc fragment containing the TM set
of substitutions. This constitutes the ﬁrst three-dimensional structure
of a human Fc fragment speciﬁcally engineered for lack of effector
functions.
2. Materials and methods
2.1. Reagents, conventions and illustrations
All chemicals were of analytical grade. Recombinant FLAG-
tagged human CD32A and CD64 were kindly provided by Linda Xu
# 2008 International Union of Crystallography
Printed in Singapore – all rights reserved(MedImmune Inc.). Recombinant FLAG-tagged human CD16 (V158
allotype) was generated as previously described (Oganesyan et al.,
2008). All antibody amino-acid positions mentioned in the text are
identiﬁed according to the EU numbering convention described in
Kabat et al. (1991). Illustrations were prepared using PyMOL
(DeLano Scientiﬁc, Palo Alto, California, USA).
2.2. Generation, expression and purification of mAb 3649 and
3649/TM
A humanized monoclonal antibody directed against human CD19
(referred to hereafter as mAb 3649) was generated at MedImmune
Inc. and used as a test molecule for studying the impact of TM on
human IgG binding to human effector molecules. The heavy and light
chains of mAb 3649 (IgG1,  ) were cloned into a previously described
mammalian expression vector (Oganesyan et al., 2008). The TM
combination of mutations was introduced into the heavy chain of
mAb 3649 by site-directed mutagenesis using a QuikChange XL
Mutagenesis Kit according to the manufacturer’s instructions (Stra-
tagene, La Jolla, California, USA). This generated mAb 3649/TM.
Human embryonic kidney (HEK) 293 cells were then transiently
transfected with the corresponding antibody constructs and the
secreted immunoglobulins were puriﬁed using HiTrap protein A
columns according to the manufacturer’s instructions (GE Health-
care, Piscataway, New Jersey, USA).
2.3. Analysis of human C1q binding to mAb 3649 and 3649/TM
In order to characterize the binding of mAb 3649 and 3649/TM to
human C1q, the following ELISAwas carried out. Individual wells of
a 96-well Maxisorp Immunoplate (Nunc, Rochester, New York,
USA) were coated for at least 2 h at 277 K with twofold serially
diluted samples (mAb 3649 or 3649/TM) at concentrations typically
ranging from 100 to 0.05 mgm l
 1 and then blocked with 4% milk for
at least 2 h at 310 K. Plates were then successively incubated with
2 mgm l
 1 human C1q (Quidel, San Diego, California, USA) for 1 h at
310 K and sheep anti-human C1q (BioDesign, Saco, Maine, USA;
1/1000 dilution) for 1 h at 310 K. Incubation with a donkey anti-sheep
IgG horseradish peroxidase conjugate (Serotec, Raleigh, North
Carolina, USA; 1/10,000 dilution) for 1 h at room temperature then
followed. Horseradish peroxidase activity was detected with TMB
substrate (KPL, Gaithersburg, Maryland, USA) and the reaction was
quenched with 1% H2SO4. Plates were read at 450 nm.
2.4. Analysis of human Fcc receptors binding to mAb 3649 and
3649/TM
In order to characterize the binding of mAb 3649 and 3649/TM to
human CD64 and CD16/V158, the following ELISAwas carried out.
Individual wells of a 96-well Maxisorp Immunoplate (Nunc) were
coated overnight at 277 K with a 10 mgm l
 1 solution of mAb 3649 or
3649/TM and blocked with 4% milk for at least 2 h at 310 K. Incu-
bation with twofold serially diluted samples (Fc  receptors) at
concentrations typically ranging from 50 to 0.02 mgm l
 1 for 1 h at
310 K then followed. Plates were successively incubated with bio-
tinylated anti-FLAG IgG (Sigma, St Louis, Missouri, USA; 1:100
dilution) and then avidin horseradish peroxidase conjugate (Pierce,
Rockford, Illinois, USA; 1:250 dilution) each for 1 h at 310 K. Plates
were developed and read as described above.
Binding of mAb 3649 and 3649/TM to human CD32Awas assessed
essentially as described above with the following modiﬁcation: in
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Figure 1
(a) Representation of the contents of the asymmetric unit of the Fc/TM crystal. The only visible mutation comprising ‘TM’, P331S, is indicated in red. One zinc ion is shown
chelated by two spatially close histidine residues. The conventional ‘horseshoe’-shaped homodimeric Fc fragment would be achieved by invoking a crystallographic twofold
symmetry operator. The carbohydrate residues attached to Asn297 were modeled according to their electron density. (b) Stereographic representation of three unliganded
human Fc regions separately superimposed through their respective CH2 and CH3 domains. Polypeptides are color-coded as follows: blue, 2ql1 (Oganesyan et al., 2008); red,
1h3w (Krapp et al., 2003); green, Fc/TM.order to increase the low ELISA signal arising from the poor afﬁnity
of the human CD32A–IgG interaction, dilutions of human CD32A
were ﬁrst dimerized by pre-incubation with a biotinylated anti-FLAG
IgG (Sigma; 1:100 dilution) for 1 h at room temperature and then
added to the IgG-coated wells.
2.5. Generation and purification of Fc/TM
The human Fc/TM fragment was obtained directly from the
enzymatic cleavage of a fully human monoclonal antibody targeting
the type I interferon receptor 1 (IgG1,  ) and whose Fc contains the
TM set of substitutions. This particular human IgG, which contained
an Fc portion identical to that of 3649/TM, was selected for digestion
owing to its availability at the time of the experiment. Digestion was
carried out using immobilized ﬁcin according to the manufacturer’s
instructions (Pierce). Puriﬁcation was ﬁrst performed on HiTrap
protein A columns according to the manufacturer’s instructions (GE
Healthcare). After dialysis in 50 mM sodium acetate pH 5.2, the
protein solution was applied onto a HiTrap SP HP column (GE
Healthcare) and collected in the ﬂowthrough. Aﬁnal puriﬁcation step
which included loading of this ﬂowthrough onto a HiTrap Q column
(GE Healthcare) and elution in an NaCl gradient yielded a homo-
genous Fc/TM preparation, as judged by reducing and nonreducing
SDS–PAGE. In particular, we note that the Fc/TM SDS–PAGE
proﬁle showed the presence of only one band around 25 or 50 kDa
under reducing or nonreducing conditions, respectively (data not
shown). This observation clearly demonstrated the presence of at
least one interchain disulﬁde bond at positions Cys226 and/or Cys229.
Consequently, the mutated ‘downstream’ residues Phe234 and
Glu235 were present in the polypeptide chain comprising the crystal.
2.6. Crystallization of Fc/TM
Puriﬁed Fc/TM was concentrated to about 5 mg ml
 1 using a
Centricon concentrator (Millipore, Billerica, Massachusetts, USA;
30 kDa cutoff). Crystallization conditions were identiﬁed using the
commercial screens from Hampton Research (Hampton Research,
Aliso Viejo, California, USA), Emerald BioSystems (Emerald
BioSystems Inc., Bainbridge Island, Washington, USA) and Mole-
cular Dimensions (Molecular Dimensions Inc., Apopka, Florida,
USA). Each screen yielded several potentially usable crystallization
conditions. Upon optimization, diffraction-quality crystals were
obtained from 0.2 M zinc acetate, 0.1 M imidazole–malate pH 8.0, 5%
PEG 3350, 5% glycerol at a protein concentration of 2.0 mg ml
 1.
Under these conditions, well shaped crystals with three dimensions
ranging from 0.1 to 0.2 mm grew in 2–3 d (see supplementary Fig. 1
1).
2.7. Data collection
Diffraction data were collected from a single crystal at the Center
for Advanced Research in Biotechnology (CARB, University of
Maryland Biotechnology Institute, Rockville, Maryland, USA) using
a Rigaku MicroMax-007 rotating-anode generator with an R-AXIS
IV
++ imaging plate (Rigaku/MSC, The Woodlands, Texas, USA).
Prior to cooling, the crystal was kept for a few minutes in its growth
solution supplemented with 20% glycerol. The crystal was then
cooled to 105 K with an X-stream 2000 low-temperature system
(Rigaku/MSC). Diffraction to 2.3 A ˚ was achieved after one round of
annealing as described in Oganesyan et al. (2008). Diffraction data
comprising 234 images were collected using an oscillation range of
0.5 , a crystal-to-detector distance of 200 mm and an exposure time of
600 s. Data were integrated and scaled using the HKL-2000 software
(Otwinowski & Minor, 1997).
2.8. Structure determination
Molecular replacement, reﬁnement and electron-density calcula-
tions were carried out using the CCP4 program suite (Collaborative
Computational Project, Number 4, 1994). The C face-centered
orthorhombic crystal had 58% solvent content and a VM of
2.9 A ˚ 3 Da
 1, assuming the presence of one Fc polypeptide in the
asymmetric unit of the cell. The crystal structure of Fc/TM was
determined by molecular replacement and reﬁned at 2.3 A ˚ resolu-
tion. Chain A of the human Fc structure corresponding to PDB entry
2dtq (Matsumiya et al., 2007) was used as the model because of its
high resolution and unliganded state. In particular, the CH2 and CH3
domains were considered separately in order to minimize any bias in
terms of the relative conformation of the domains. Data to 3.0 A ˚
resolution were used to solve the molecular-
replacement problem using Phaser (McCoy et al.,
2005). After reﬁnement of the solutions, the ﬁnal
LL gain and the Z score were 1192 and 31,
respectively. Weighted electron density calcu-
lated with FWT/PHWT at 3.0 A ˚ showed a good
match to the model, with minor differences in
some loops of the CH2 domain. Strong positive
difference electron density calculated with
DELFWT/PHDELWT was visible in the
expected position of N-linked carbohydrate
residues attached to Asn297. There was no
density present for any hinge residue preceding
that at position 236, a result presumably attri-
butable to the high ﬂexibility of this region. To
this effect, we note that only two previously
described unliganded human Fc structures
revealed positions 234 and 235 (PDB codes 2dtq
and 2dts; Matsumiya et al., 2007). Likewise, the
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Figure 2
Stereographic superimposition of Fc/TM with the CD16-liganded human Fc structure corresponding to
PDB code 1e4k (Sondermann et al., 2000). Superimposition of C
  atoms of Fc/TM and 1e4k (CH2 domain
residues 236–342) was carried out using LSQKAB (Kabsch, 1976). For both chains of 1e4k, the r.m.s.
displacement was estimated at 1.9 A ˚ , with a maximum displacement of 6.4 A ˚ for the C
  of residue 286.
Human CD16 and Fc/TM are colored green and orange, respectively. Chains A and B of 1e4k are colored
red and blue, respectively.
1 Supplementary material has been deposited in the
IUCr electronic archive (Reference: MH5013).
Services for accessing this material are described at
the back of the journal.residues at positions 446 and 447 could not be visualized. The residue
at position 331 was ﬁrst modeled as an alanine.
Several alternating rounds of reﬁnement with REFMAC5
(Murshudov et al., 1997) and manual building using the O graphics
software (Jones et al., 1991) converged with an R factor of 21.6 and a
free R factor of 27.5 for data to 2.3 A ˚ resolution. After the ﬁrst round
of reﬁnement, the electron density allowed placement of the carbo-
hydrates as well as substitution by a serine residue at position 331. In
later stages of reﬁnement, the model was analyzed using the TLS
Motion Determination (TLSMD) program running on its web server
(Painter & Merritt, 2006a,b). Further reﬁnement was then carried out
with REFMAC5 in TLS and restrained reﬁnement mode using ﬁve
distinct groups of residues (236–324, 325–341, 342–358, 359–403 and
404–445). Zinc ions present in the crystallization buffer were detected
in the electron density and modeled as such when the coordination
sphere and distance permitted. In particular, one zinc ion was found
to be coordinated by His310 and His435. Another was coordinated by
His285 and His268 of the symmetry-related polypeptide. Two others
were bound to Glu318 and Glu345. In all cases, water molecules
completed the expected tetrahedral coordination sphere of the zinc
ions. The carbohydrate moiety was modeled according to its electron
density and the ﬁnal model contained nine sugar residues, essentially
as described by us in the context of another human Fc structure (PDB
code 2ql1; Oganesyan et al., 2008). The ﬁnal model contained 75
solvent molecules. Crystallographic data and reﬁnement statistics are
given in Table 1.
3. Results and discussion
Fc/TM crystallized in space group C2221, with one polypeptide in the
asymmetric unit (Fig. 1a). The crystal diffracted to 2.3 A ˚ resolution
and exhibited a relatively high average mosaicity of 1.26 . This high
mosaicity appeared to be a property of both cooled and noncooled
crystals. All residues at positions 236–445 could be traced in the
electron density. As mentioned above, no electron density was
observed for hinge residues prior to position 236. Thus, although
present in the crystal (see x2), both the L234F and L235E mutations
were invisible. As expected, the electron density at position 331
corresponded to serine (see supplementary Fig. 2).
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Figure 3
Analysis of the binding of human (a) CD64, (b) CD32A, (c) CD16/V158 and (d) C1q to mAb 3649 and 3649/TM. Measurements were carried out using an ELISA format as
described in x2. Errors were estimated as the standard deviations of at least two individual measurements for each interacting pair. The illegibility of the error bars for some
data points is the direct result of the corresponding very low standard deviations. Data shown are representative of at least two independent series of experiments.
Table 1
X-ray data-collection and model-reﬁnement statistics.
Values in parentheses are for the highest resolution shell.
Wavelength (A ˚ ) 1.54
Resolution (A ˚ ) 36.83–2.30 (2.38–2.30)
Space group C2221
Unit-cell parameters (A ˚ ) a = 50.18, b = 147.30,
c = 75.47
Total reﬂections 54409
Unique reﬂections 12617
Average redundancy 4.31 (2.72)
Completeness (%) 98.3 (90.0)
Rmerge 0.062 (0.300)
I/ (I) 13.0 (3.3)
R factor/free R factor 0.216/0.275
R.m.s.d. bonds (A ˚ ) 0.012
R.m.s.d. angles ( ) 1.48
Residues in most favored region of (’,  ) space† (%) 89.9
Residues in additionally allowed region of (’,  ) space (%) 10.1
No. of protein atoms 1678
No. of nonprotein atoms 189
B factor (model/Wilson) (A ˚ 2) 43/40
† The Ramachandran plot was produced using PROCHECK (Laskowski et al., 1993).The overall three-dimensional structure of Fc/TM was very similar
to the previously reported structures of unliganded human Fc regions
(Deisenhofer, 1981; Krapp et al., 2003; Matsumiya et al., 2007;
Oganesyan et al., 2008). More precisely, the human Fc structures
corresponding to PDB codes 1h3w (Krapp et al., 2003) and 2ql1
(Oganesyan et al., 2008) were closest to Fc/TM in terms of unit-cell
parameters, asymmetric unit content, space group and packing. The
extent of this similarity was evident when the three structures were
superimposed (Fig. 1b). Corresponding r.m.s.d. values are shown in
Table 2. This overall structural conservation extended to a previously
described human Fc in complex with human CD16 (PDB code 1e4k;
Sondermann et al., 2000), including the intermolecular contact
interface (see Fig. 2).
The introduction of TM into the Fc of human IgG1s resulted in an
almost complete loss of their binding to several effector molecules
(CD64, CD32A, CD16 and C1q) as shown in Fig. 3. In addition, the
three-dimensional structure of Fc/TM was found to be very similar to
that of other liganded and unliganded human Fc fragments in the
region spanning residues 236–445 (see above). Thus, we conclude that
the dramatic broad-ranging functional effects of the TM set of
substitutions were not caused by major structural rearrangements in
this portion of Fc/TM. Although no deﬁnitive statement can be made
for the ‘unseen’ positions 234 and 235, we hypothesize that these
effects may be mediated by the localized loss of a few interactions at
the mutation sites. However, we cannot rule out that one or more of
the mutations described in this work might also trigger major struc-
tural changes in other unseen parts of the Fc, such as in the lower or
middle hinge regions.
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Table 2
Structural comparison of three unliganded human Fc structures.
Molecule pair Residue span R.m.s.d. (A ˚ )
Fc/TM†–2ql1‡ 236–444 (CH2/CH3) 0.51
Fc/TM–1h3w§ 238–444 (CH2/CH3) 1.27
2ql1–1h3w 238–444 (CH2/CH3) 1.29
Fc/TM–2ql1 236–342 (CH2) 0.61
Fc/TM–2ql1 342–444 (CH3) 0.36
Fc/TM–1h3w 238–342 (CH2) 1.58
Fc/TM–1h3w 342–444 (CH3) 0.43
2ql1–1h3w 238–342 (CH2) 1.58
2ql1–1h3w 342–444 (CH3) 0.37
† This study (PDB code 3c2s). ‡ Oganesyan et al. (2008). § Krapp et al. (2003).